<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-QSB
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended May 31, 1997 or
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from ___________ to ____________
Commission file number 000-21665
--------------------------------------------------
SIMULATIONS PLUS, INC.
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Its Charter)
CALIFORNIA 95-4595609
- ------------------------------------- -------------------------------------
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification No.)
40015 Sierra Highway, B-110, Palmdale, CA 93550
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(805) 266-9294
- --------------------------------------------------------------------------------
(Registrant's Telephone Number, including Area Code)
Not Applicable
- --------------------------------------------------------------------------------
(Former Name, Former Address and Former Fiscal Year, if Changed
Since Last Report)
Indicate by check mark whether the registrant: (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes No X
--------- ---------
The number of shares outstanding of the Issuer's common stock, par
value $0.001 per share, as of August 8, 1997, was 3,350,000.
1
<PAGE> 2
SIMULATIONS PLUS, INC.
FORM 10-QSB
For the Quarterly Period Ended May 31, 1997
INDEX
<TABLE>
<CAPTION>
Page No.
--------
<S> <C> <C>
PART 1. FINANCIAL INFORMATION
Item 1. Financial Statements
Consolidated Balance Sheet at May 31, 1997 (unaudited) 3
Consolidated Statements of Operations for the three and
nine months ended May 31, 1997 and 1996 (unaudited) 4
Consolidated Statements of Cash Flows for the nine months
ended May 31, 1997 and 1996 (unaudited) 5
Notes to Consolidated Financial Statements (unaudited) 6
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations 9
PART II. OTHER INFORMATION 15
</TABLE>
2
<PAGE> 3
SIMULATIONS PLUS, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEET
May 31,1997
(Unaudited)
<TABLE>
<CAPTION>
<S> <C>
ASSETS
Current assets:
Cash 0
Accounts receivable, net of allowance for 300,491
doubtful accounts of $7,000
Due from officer (note 7) 40,000
Income tax receivable 76,057
Inventory 147,941
---------
Total Current Assets 564,489
---------
Capitalized computer software development costs,
net of accumulated amortization (note 5) 648,494
Furniture and equipment, net (note 2) 187,192
Other assets 44,927
Deferred offering costs 590,770
---------
2,035,872
---------
LIABILITIES AND SHAREHOLDER'S EQUITY (DEFICIT)
Current liabilities:
Book overdraft 27
Notes payable (note 3) 1,650,000
Line of Credit 98,010
Accounts payable 320,456
Accrued interest 76,978
Accrued compensation due to officer (note 7) 150,000
Accrued payroll and other expenses 119,643
Accrued warranty and service costs 39,815
Current portion of capitalized lease obligations 24,414
---------
Total Current liabilities 2,479,343
---------
Capitalized lease obligations, net of current portion 65,004
---------
Total Liabilities 2,544,347
---------
Shareholders' equity (deficit)
Common stock: $.001 par value, authorized
20,000,000 shares, issued and outstanding 2,200,000 (note 4) 2,200
Additional paid-in capital 116,667
Accumulated deficit (627,342)
---------
Total shareholders' equity (deficit) (508,475)
---------
2,035,872
=========
</TABLE>
The accompanying footnotes are an integral part of these statements.
3
<PAGE> 4
SIMULATIONS PLUS, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS
For the three and nine months ended May 31, 1997 and 1996
(Unaudited)
<TABLE>
<CAPTION>
Three months ended Nine months ended
-------------------------------------- --------------------------------
May 31, '97 May 31, '96 May 31, '97 May 31, '96
--------------- ------------- ------------- -------------
<S> <C> <C> <C> <C>
Net sales 560,162 621,021 1,779,726 1,982,431
Cost of sales 288,513 380,313 856,811 1,042,787
---------- ---------- ---------- ----------
Gross Profit 271,649 240,708 922,915 939,644
---------- ---------- ---------- ----------
Operating expenses:
Selling, G & A 497,335 234,934 1,435,813 836,677
Research and Development 28,885 34,892 84,761 79,482
---------- ---------- ---------- ----------
Total Operating Expenses 526,220 269,826 1,520,574 916,159
---------- ---------- ---------- ----------
Income (loss) from operations (254,571) (29,118) (597,659) 23,485
Other income (expenses):
Income from grant 0 17,159 17,159 17,159
Interest revenue 693 0 1,951 0
Financing costs (105,833) 0 (187,500) 0
Interest expense (40,000) (2,034) (90,480) (4,045)
---------- ---------- ---------- ----------
Income (loss) before provision for Income taxes (399,711) (13,993) (856,529) 36,599
Provision (benefit) for income taxes 0 (4,377) (38,800) 10,811
---------- ---------- ---------- ----------
Net income (loss) (399,711) (9,616) (817,729) 25,788
========== ========== ========== ==========
Net income (loss) per share (0.17) (0.00) (0.34) 0.01
========== ========== ========== ==========
Weighted Ave. # of common shares
outstanding 2,390,000 2,390,000 2,390,000 2,390,000
</TABLE>
The accompanying footnotes are an integral part of these statements.
4
<PAGE> 5
SIMULATIONS PLUS, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS
For the nine months ended May 31, 1997 and 1996
(Unaudited)
<TABLE>
<CAPTION>
Nine months ended
--------------------------------
May 31, '97 May 31, '96
----------- -----------
<S> <C> <C>
Cash flows from operating activities:
Net income (loss) (817,729) 25,788
Adjustments to reconcile net income (loss) to net cash
provided by (used in) operating activities:
Depreciation and amortization of furniture and equipment 27,751 13,827
Amortization of capitalized software development costs 55,858
Issuance of warrants for financing costs 116,667
Amortization of loan origination fees 70,833 45,173
Deferred taxes 380 5,700
(Increase) decrease in:
Accounts receivable (51,077) 24,878
Inventory (76,810) (15,384)
Other assets (18,988) (3,296)
Increase (decrease) in:
Accounts payable 142,968 (48,494)
Accrued interest 76,978
Accrued payroll and other expenses 46,179 12,336
Accrued warranty and service costs 1,374 (406)
Income tax payable (40,780) (38,230)
---------- -------
Net cash provided by (used in) operating activities (466,396) 21,892
---------- -------
Cash flows from investing activities:
Advance to officer (40,000)
Purchase of furniture and equipment (58,671) (9,755)
Capitalized computer software development cost (481,410) (53,347)
---------- -------
Net cash (used in) investing activities (580,081) (63,102)
---------- -------
Cash flows from financing activities:
Increase in book overdraft 27 34,894
Proceeds from line of credit, net 4,471 31,982
Payments on capitalized lease obligations (14,648) (15,695)
Due to officer, net (34,148)
Increase in deferred offering costs (567,473)
Proceeds from notes payable 1,450,000
---------- -------
Net cash provided by financing activities 872,377 17,033
---------- -------
Net decrease in cash (174,100) (24,177)
Cash, beginning of period 174,100 24,177
---------- -------
Cash, end of period 0 0
========== =======
</TABLE>
The accompanying footnotes are an integral part of these statements.
5
<PAGE> 6
SIMULATIONS PLUS, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(Unaudited)
Note 1: GENERAL
As contemplated by the Securities and Exchange Commission under Item 310(b) of
Regulation S-B, the accompanying financial statements and footnotes have been
condensed and therefore do not contain all disclosures required by generally
accepted accounting principles. The interim financial data are unaudited;
however, in the opinion of Simulations Plus, Inc. (the "Company"), the interim
data include all adjustments, consisting only of normal recurring adjustments,
necessary for a fair statement of the results for the interim periods. Results
for interim periods are not necessarily indicative of those to be expected for
the full year.
Note 2: FURNITURE AND EQUIPMENT
<TABLE>
<S> <C>
Furniture and equipment consist of the following:
Equipment . . . . . . . . . . . . . . . . . . . . . . . . . . $ 39,456
Computer equipment . . . . . . . . . . . . . . . . . . . . . . 294,756
Furniture and fixtures . . . . . . . . . . . . . . . . . . . . 43,923
Leasehold improvements . . . . . . . . . . . . . . . . . . . . 5,900
--------
384,035
Less accumulated depreciation . . . . . . . . . . . . . . . . 196,843
--------
$187,192
========
</TABLE>
Note 3: PROMISSORY NOTES PAYABLE
In August 1996, the Company entered into a Subscription Agreement whereby the
Company issued a note in the amount of $200,000 and issued 100,000 Warrants to
purchase Common Stock. The Warrants are exercisable at $4.00 per share and
expire five years from the date of grant. The note was collateralized by the
Company's accounts receivable and inventory, and bears interest at 10%. The note
was to be repaid at the earlier of June 30, 1997 or five days after the close of
the Company's initial public offering ("IPO"). (This note was repaid after the
Company's IPO in June 1997.)
In September 1996, the Company entered into a Subscription Agreement whereby the
Company issued a note in the amount of $300,000 and issued 150,000 Warrants to
purchase Common Stock. The Warrants are exercisable at $4.00 per share and
expire five years from the date of grant. The note was collateralized by the
Company's accounts receivable and inventory, and bears interest at 10%. The note
was to be repaid at the earlier of June 30, 1997 or five days after the close of
the Company's initial public offering. (This note was repaid after the Company's
IPO in June 1997.)
In October 1996, the Company purchased pharmaceutical simulation software
packages from Dr. Michael Bolger for an aggregate of $100,000. The purchase
price was paid $50,000 upon
6
<PAGE> 7
execution of the purchase agreement and the remaining $50,000 was evidenced by a
promissory note bearing interest at 8% per annum, and was due the earlier of one
year from the date of such note or seven days after the closing of the Company's
IPO. (This note was repaid after the Company's IPO in June 1997.)
In December 1996 and January 1997, the Company entered into Subscription
Agreements whereby the Company issued 10% promissory notes (the "Bridge Notes")
in the aggregate amounts of $1,100,000 to certain lenders (the "Bridge Lenders")
and issued 280,000 Warrants (the "Bridge Warrants") to purchase Common Stock.
The Bridge Warrants are exercisable at $2.50 per share and expire five years
from the date of grant. The Bridge Lenders have agreed not to resell or
otherwise transfer such Bridge Warrants or the shares of Common Stock issuable
upon exercise thereof until 365 days after the completion of the Company's
public offering. The principal and unpaid interest on the Bridge Notes were due
at the earlier of December 31, 1997 or five days after the close of the
Company's IPO. (These notes were repaid after the Company's IPO in June 1997.)
Note 4: STOCKHOLDERS' EQUITY
Initial Public Offering
On June 18, 1997, the Company completed an IPO of 1,150,000 shares, resulting in
net proceeds to the Company of approximately $4,400,000 after paying
underwriters' fees and costs associated with the offering.
Issuance of Warrant
The Company issued to the underwriters in the IPO, in consideration for $100, a
warrant to purchase 115,000 shares, at a per share exercise price of $6.00 per
share. The warrant is exercisable through June 17, 2001.
Cost associated with the issuance of warrants
In connection with issuance of the Bridge Notes and Bridge Warrants, the Company
concluded that a 30% discount from the IPO price was the value to be accorded to
the Bridge Warrants given that the Bridge Warrants are locked up for 12 months
and allowing for the level of risk involved with the IPO. The resulting value of
$3.50 per share is $1.00 per share higher than the exercise price of the
warrants. Accordingly, the Company will amortize a financing cost of $280,000
over a twelve-month period with the unamortized potion at the date of the IPO
being charged to earnings as an extraordinary financing charge.
Note 5: SOFTWARE DEVELOPMENT COSTS
Software development costs are capitalized in accordance with Statement of
Financial Accounting Standards (SFAS) No. 86 "Accounting for the Cost of
Computer Software to be Sold, Leased or Otherwise Marketed." Capitalization of
software development costs begins upon the establishment of technological
feasibility and is discontinued when the product is
7
<PAGE> 8
available for sale. The establishment of technological feasibility and the
ongoing assessment for recoverability of capitalized software development costs
require considerable judgment by management with respect to certain external
factors, including, but not limited to, technological feasibility, anticipated
future gross revenues, estimated economic life, and changes in software and
hardware technologies. Capitalized software development costs are comprised
primarily of salaries and direct payroll related costs, and the purchase of
existing software to be used in the Company's software products.
Amortization of capitalized software development costs is provided on a
product-by-product basis on the straight-line method over the estimated economic
life of the products (not to exceed three years). Management periodically
compares estimated net realizable value by product to the amount of software
development costs capitalized for that product to ensure the amount capitalized
is not in excess of the amount to be recovered through revenues. Any such excess
of capitalized software development costs to the expected net realizable value
is expensed at that time.
Note 6: Income Taxes
The Company used the liability method of accounting for income tax pursuant to
SFAS No. 109 "Accounting for Income Taxes."
Note 7: Related Party Transactions
Accrued compensation due to officer in the consolidated balance sheet represents
accrued salary due to the Company's President and is payable on demand. The
amount does not accrue interest and will be paid from the proceeds of the
Company's IPO. (The amount due was paid after the Company's IPO in June 1997.)
In January 1997, the Company's President borrowed $40,000 from the Company. The
amount bears interest at 10% per annum and is to be repaid at the demand of the
Company. (The President of the Company paid this note to the Company in June
1997.)
8
<PAGE> 9
Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations
The following discussion should be read in conjunction with the financial
statements and the notes thereto appearing elsewhere in the Form 10-QSB.
GENERAL
Simulations Plus, Inc. ("Simulations Plus" or the "Company") was incorporated
in 1996 to develop, market and support software for the educational and
pharmaceutical industries, and to continue the operations of its wholly-owned
subsidiary, Words+, Inc., which was incorporated in 1981. Words+, Inc. develops,
markets and supports hardware and software products for persons with severe
disabilities.
Simulations Plus's existing products consist of the first three of its
FutureLabTM educational simulation software titles, which were released in May
1997. These are: Circuits for Physical Science, Gravity for Physical Science,
and Optics for Physical Science. In addition, other FutureLab titles are under
development and over 20 new titles are currently expected to be released during
the Company's FY 98, which begins September 1, 1997. No assurance can be given
that the Company will be able to deliver and release such number of new titles
during FY 98.
Simulations Plus is also involved in the development of simulation software for
the pharmaceutical industry. Two programs are currently under development:
HelixGen and GASTRO. HelixGen is being designed to predict the shape of the
receptor sites of certain transmembrane proteins for the purpose of analytically
determining whether new candidate drug compounds will bind to those sites.
GASTRO is being designed to predict the rate and location of absorption of new
candidate drug compounds in the human gastro-intestinal tract for the purpose of
determining whether new candidate drug compounds will be absorbed into the blood
stream from the gastro-intestinal tract. There can be no assurance that the
Company will achieve sufficient economic utility in the simulation models it
develops, or even if it does, that it will be able to market a sufficient number
of such simulations at a profitable price.
Words+, Inc.'s products consist of a catalog of software and hardware products
designed to provide communication and computer access for persons with severe
disabilities. The Company's most famous user is theoretical astrophysicist
Professor Stephen Hawking, author of the best-selling A Brief History of Time.
The Company's Pegasus LITE communication device received a Computerworld
Smithsonian Finalist Award in June 1997.
RESULTS OF OPERATIONS
COMPARISON OF THREE MONTHS ENDED MAY 31, 1997 AND 1996.
The following sets forth selected items from the Company's statements of
operations (in thousands) and the percentages that such items bear to net sales:
9
<PAGE> 10
Net Sales
Net sales decreased $61,000, or 9.8%, to $560,000 in the third fiscal quarter of
1997 from $621,000 in the third fiscal quarter of 1996 primarily due to two
factors: (1) slow market acceptance of the Company's Pegasus LITE communication
device, and (2) changing from a higher-priced hardware voice synthesizer to a
lower-priced voice synthesizer for a significant percentage of its computer
based products.
Cost of Sales
Cost of sales decreased $92,000, or $24.0%, to $288,000 in the third fiscal
quarter of 1997 from $380,000 in the third fiscal quarter of 1996 primarily due
to the conversion from a hardware voice synthesizer to a lower-priced software
voice synthesizer. As a percentage of net sales, cost of sales was 51.5% in the
third fiscal quarter of 1997 compared to 61.2% in 1996. Management attributes
this decrease primarily to the conversion from the hardware voice synthesizer to
the software voice synthesizer.
Selling, General and Administrative Expenses
Selling, general and administrative expenses increased $262,000, or 111.5%, to
$497,000 in the third fiscal quarter of 1997 from $235,000 in the third fiscal
quarter of 1996 primarily due to increased personnel costs resulting from the
hiring of additional personnel, expansion of office space, and other associated
overhead costs in 1997 in support of accelerated activities associated with new
simulation software development.
Research and Development
The Company incurred $35,000 of research and development costs during the third
quarter of 1996 and the entire $35,000 was expensed. In the third quarter of
1997, the Company incurred $162,000 of research and development costs, of which
$133,000 was capitalized and $29,000 was expensed. The 363% increase in research
and development expenditure from the third quarter of 1996 to the third quarter
of 1997 was due to the new development of educational and pharmaceutical
simulation software begun in September 1996.
Income from Grant
During the third quarter of FY 1996, the Company received the first $17,000 of a
$51,000 Phase I SBIR grant from the National Science Foundation to develop
software to allow physically-disabled students to perform simulated laboratory
experiments on a computer, which became the beginning of the development of the
FutureLab series of educational simulation software.
Interest Expense
Interest expense for the third quarter of 1997 increased by $38,000, or 1,900%,
to $40,000 from $2,000 in the third quarter of 1996. This increase is
attributable primarily to the finance charges incurred for the Bridge Notes and
the notes issued in August and September 1996.
10
<PAGE> 11
Financing Costs
Financing costs for the three months ended May 31, 1997 was $105,833 compared to
$0 for the three months ended May 31, 1996. The increase is due to the
amortization of loan origination fees of $35,833 and the value attributed to the
280,000 warrants issued in December 1996 and January 1997 of $280,000, which is
being amortized over the term of the loans. Any unamortized portion of this
additional financing cost at the completion of the Company's IPO will be charged
to earnings as an extraordinary loss on debt extinguishment.
Net Income
Net income for the three months ended May 31, 1997 declined by $390,000, or
3,900%, to a net loss of $400,000 compared to a net loss of $10,000. Management
attributes this decline primarily to the decrease in Net Sales, the increase in
Selling, General and Administrative expenses incurred by the Company for its
research and development efforts, and the increased financing costs and interest
expenses compared to the three months ended May 31, 1996.
COMPARISON OF NINE MONTHS ENDED MAY 31, 1997 AND 1996.
The following sets forth selected items from the Company's statements of
operations (in thousands) and the percentages that such items bear to net sales:
Net Sales
Net sales decreased $202,000 or 10.2%, to $1,780,000 for the nine months ended
May 31, 1997, compared to $1,982,000 for the nine months ended May 31, 1996.
Management attributes this decrease primarily to two factors: (1) changing from
a higher-priced hardware voice synthesizer to a lower-priced software voice
synthesizer for a high percentage of its computer-based products and (2) slow
market acceptance of the Pegasus LITE communication device.
In April 1996, the Company began shipping a new software voice synthesizer with
a significant number of its computer-based communication systems. This software
voice synthesizer has a retail price of $199, whereas the hardware voice
synthesizer it replaced had a retail price of $1,195. This reduced the average
revenues per sale for such systems by approximately $1,000 per system.
Cost of Sales
Cost of sales for the nine months ended May 31, 1997 decreased by $186,000, or
17.8% to $857,000 compared to $1,043,000 for the nine months ended May 31, 1996.
As a percentage of net sales, cost of sales was 48.1% for the nine months ended
May 31, 1997 compared to 52.6% for the nine months ended May 31, 1996.
Management attributes this decrease of $186,000 in cost of sales primarily to
the conversion from the hardware voice synthesizer to the software voice
synthesizer.
11
<PAGE> 12
Selling, General and Administrative Expenses
Selling, general and administrative expenses for the nine months ended May 31,
1997 increased by $599,000, or 71.6% to $1,436,000 compared to $837,000 for the
nine months ended May 31, 1996. As a percentage of net sales, selling, general
and administrative expenses increased from 42.2% to 80.7% for the nine months
ended May 31, 1997. Management attributes this increase primarily to increased
personnel costs resulting from the hiring of additional personnel, expansion of
office space, and other associated overhead costs in 1997 in support of
accelerated activities associated with new simulation software development. The
Company's direct mailing, advertising and conference expenses increased by
$123,000, or 232% to $176,000 for the nine months ended May 31, 1997 compared to
$53,000 for the nine months ended May 31, 1996.
Research and Development
The Company incurred approximately $566,000 of research and development costs
for the nine months ended May 31, 1997, of which approximately $481,000 was
capitalized and approximately $85,000 was expensed. For the nine months ended
May 31, 1996, the Company incurred approximately $132,000 of research and
development costs, of which approximately $53,000 was capitalized and
approximately $79,000 was expensed. The 328.8% increase in research and
development expenditures for the nine months ended May 31, 1997 was primarily
due to new development work on educational and pharmaceutical simulation
software.
Income from Grant
For the nine months ended May 31, 1997, the Company received $17,000, the last
one-third of a $51,000 Phase I SBIR grant from the National Science Foundation
to develop software to allow physically-disabled students to perform simulated
laboratory experiments on a computer. For the nine months ended May 31, 1996,
the Company received the first one-third of this grant.
Interest Expense
Interest expense for the nine months ended May 31, 1997 increased $86,000, or
2150%, to $90,000 from $4,000 in the nine months ended May 31, 1996. This
increase is primarily due to the finance charges incurred for the Bridge Notes
and notes issued in August and September 1996.
Financing Costs
Financing costs for the nine months ended May 31, 1997 were $187,500 compared to
$0 for the nine months ended May 31, 1996. The increase is due to the
amortization of loan origination fees of $70,833 that is being amortized over
the term of the Bridge Notes. Any unamortized portion of this additional
financing cost at the completion of the Company's IPO will be charged to
earnings as an extraordinary loss on debt extinguishment.
Income Taxes
Income taxes decreased $50,000, or 455% to the tax benefit of $39,000 from the
provision of $11,000 for the nine months ended May 31, 1996 because of the
Company's decreased earnings.
12
<PAGE> 13
Net Income
Net income for the nine months ended May 31, 1997 declined by $844,000, or
3,246%, to the net loss of $818,000 compared to the net income of $26,000.
Management attributes this decline primarily to the decrease in Net Sales, the
increase in Selling, General and Administrative expenses incurred by the Company
for its research and development efforts, and the increased financing costs and
interest expenses compared to the nine months ended May 31, 1996.
LIQUIDITY AND CAPITAL RESOURCES
The Company's principal sources of capital have been cash flows from its
operations, a bank line of credit, the private placement of Promissory Notes, a
government grant, and cash loans from the officers on an as-needed basis. All
indebtedness to the officers was repaid during 1996.
The Company has available a $100,000 revolving line of credit from a bank.
Interest is payable on a monthly basis at the bank's prime rate plus 3.0%. The
revolving line of credit is not secured by any of the assets of the Company but
is personally guaranteed by Mr. Walter S. Woltosz, the Company's Chief Executive
Officer, President and Chairman of the Board of Directors.
Fernando Zamudio, one of the Selling Shareholders, advanced to the Company
$200,000 in August 1996 and Patricia Ann O'Neil, another Selling Shareholder,
advanced to the Company $300,000 in September 1996 pursuant to Promissory Notes
bearing interest at 10% per annum and were due and payable upon the earlier of
June 30, 1997 or five business days following the completion of the Company's
initial public offering. Such loans were secured by the inventory and accounts
receivable of the Company and Words+. The purpose of these loans was to help
finance the costs of the Company's IPO and ongoing operations of the Company. In
connection with the loans, the Company granted Dr. Zamudio and Ms. O'Neil
five-year warrants, with registration rights, to purchase an aggregate of
100,000 and 150,000 shares, respectively, exercisable at $4.00 per share. Dr.
Zamudio and Ms. O'Neil have no relationship with the Company, its directors,
officers or affiliates. (These notes were repaid after the Company's IPO in June
1997.)
After the Company was informed by the Janda, Phillips & Garrington, The Capital
Markets Division of Financial West Group that it was withdrawing from conducting
the Company's IPO in November 1996, the Company, in December 1996 and January
1997, raised an aggregate of $1,100,000 in gross proceeds from the Private
Placement of the Bridge Notes. The Bridge Notes mature on December 31, 1997, if
not previously paid. The Bridge Notes bear interest at the rate of ten percent
per annum. In connection with these notes, the Company issued Warrants for the
purchase of 280,000 shares of Common Stock at the price of $2.50 per share. The
proceeds from the sale of the Bridge Notes were used to help finance the costs
of the IPO and the ongoing operations of the Company. (The Bridge Notes were
repaid after the Company's IPO in June 1997.)
The Company believes that the net proceeds from the sale of the shares of Common
Stock offered in the IPO, together with existing capital and anticipated funds
from operations, will be sufficient to meet its anticipated cash needs for
working capital and capital expenditures for at
13
<PAGE> 14
least the next 13 months. Thereafter, if cash generated from operations is
insufficient to satisfy the Company's capital requirements, the Company may have
to sell additional equity or debt securities or obtain expanded credit
facilities. In the event such financing is needed in the future, there can be no
assurance that such financing will be available to the Company, or, if
available, that it will be in amounts and on terms acceptable to the Company.
14
<PAGE> 15
PART II. OTHER INFORMATION
Item 1. LEGAL PROCEEDINGS
None.
Item 2. CHANGES IN SECURITIES
None.
Item 3. DEFAULTS UPON SENIOR SECURITIES
None.
Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None.
Item 5. OTHER INFORMATION
None.
Item 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits:
27.1 Financial Data Schedule.
(b) Reports on Form 8-K
None.
15
<PAGE> 16
SIGNATURE
In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
Simulations Plus, Inc.
Date: August 8, 1997 By: /s/ MOMOKO BERAN
-------------------------------
Momoko Beran
Chief Financial Officer
16
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> AUG-31-1997
<PERIOD-START> SEP-01-1996
<PERIOD-END> MAY-31-1997
<CASH> 0
<SECURITIES> 0
<RECEIVABLES> 307,491
<ALLOWANCES> 7,000
<INVENTORY> 147,941
<CURRENT-ASSETS> 564,489
<PP&E> 384,035
<DEPRECIATION> 196,843
<TOTAL-ASSETS> 2,035,872
<CURRENT-LIABILITIES> 2,479,343
<BONDS> 0
0
0
<COMMON> 2,200
<OTHER-SE> (510,675)
<TOTAL-LIABILITY-AND-EQUITY> 2,035,872
<SALES> 1,779,726
<TOTAL-REVENUES> 1,779,726
<CGS> 856,877
<TOTAL-COSTS> 1,520,574
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 277,980
<INCOME-PRETAX> (856,529)
<INCOME-TAX> (38,800)
<INCOME-CONTINUING> (817,729)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (817,729)
<EPS-PRIMARY> (0.34)
<EPS-DILUTED> 0
</TABLE>
